Popular Trials
Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
Monoclonal Antibodies
Pembrolizumab + Chemotherapy for Non-Small Cell Lung Cancer
This trial is testing the combination of pembrolizumab with different chemotherapies and/or other immunotherapy drugs to see if it is more effective and has fewer side effects than other treatments for people with squamous or non-squamous NSCLC.
Popular Filters
Trials for Non-Small Cell Lung Cancer Patients
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
Durvalumab + SABR for Non-Small Cell Lung Cancer
This trial is testing a new drug, durvalumab, to see if it can help reduce the growth of lung cancer in combination with a type of radiation therapy called SABR. The trial will enroll 105 subjects who will be randomly assigned to receive either the combination therapy or SABR alone. Follow-up visits will be conducted to monitor subjects' health and collect blood samples to study the effects of the drug and radiation therapy.
ALK Inhibitor
Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial is testing whether a new drug, lorlatinib, is better than the standard drug, crizotinib, at treating patients with a certain type of lung cancer who have not yet received treatment.
Trials for NSCLC Patients
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
Durvalumab + SABR for Non-Small Cell Lung Cancer
This trial is testing a new drug, durvalumab, to see if it can help reduce the growth of lung cancer in combination with a type of radiation therapy called SABR. The trial will enroll 105 subjects who will be randomly assigned to receive either the combination therapy or SABR alone. Follow-up visits will be conducted to monitor subjects' health and collect blood samples to study the effects of the drug and radiation therapy.
ALK Inhibitor
Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial is testing whether a new drug, lorlatinib, is better than the standard drug, crizotinib, at treating patients with a certain type of lung cancer who have not yet received treatment.
Trials for PD-L1 Positive Patients
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
Monoclonal Antibodies
AZD7789 for Cancer
This trial is testing a new medicine called AZD7789 that helps the immune system fight advanced solid tumors by blocking proteins that hide cancer cells. It aims to see if the medicine is safe and effective for patients whose cancer has progressed despite other treatments.
Trials for EGFR Positive Patients
Tyrosine Kinase Inhibitor
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
This trial tests Lazertinib and Amivantamab for patients with advanced lung cancer with specific mutations. Lazertinib stops cancer cell growth, while Amivantamab helps the immune system kill these cells.
Survivorship and Palliative Care Model for Lung Cancer
This trial tests a supportive care model called POISE for patients with advanced lung cancer. It involves multiple sessions with a palliative care specialist to help manage emotional and psychological issues. The goal is to see if this approach reduces patient distress and improves their ability to cope with cancer.
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
Phase 3 Trials
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
ALK Inhibitor
Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial is testing whether a new drug, lorlatinib, is better than the standard drug, crizotinib, at treating patients with a certain type of lung cancer who have not yet received treatment.
Selpercatinib for Non-Small Cell Lung Cancer
This trial is testing if the drug selpercatinib can safely and effectively prevent lung cancer from returning in patients who have had treatment. It focuses on people with early-stage lung cancer. The drug works by blocking proteins that help cancer cells grow.
Trials With No Placebo
ALK Inhibitor
Alectinib vs Chemotherapy for Non-Small Cell Lung Cancer
This trial is investigating whether the drug alectinib is more effective than platinum-based chemotherapy in treating cancer, and is looking at the safety of both treatments. Participants will receive alectinib or platinum-based chemotherapy and then be followed up to see how their disease progresses.
Immunotherapy Combination
Immunotherapy Combinations for Non-Small Cell Lung Cancer
This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.
PD-L1 Inhibitor
Durvalumab + SABR for Non-Small Cell Lung Cancer
This trial is testing a new drug, durvalumab, to see if it can help reduce the growth of lung cancer in combination with a type of radiation therapy called SABR. The trial will enroll 105 subjects who will be randomly assigned to receive either the combination therapy or SABR alone. Follow-up visits will be conducted to monitor subjects' health and collect blood samples to study the effects of the drug and radiation therapy.
ALK Inhibitor
Lorlatinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial is testing whether a new drug, lorlatinib, is better than the standard drug, crizotinib, at treating patients with a certain type of lung cancer who have not yet received treatment.
View More Related Trials
Frequently Asked Questions
Introduction to non-small cell lung cancer
What are the top hospitals conducting non-small cell lung cancer research?
When it comes to cutting-edge clinical trials in the battle against non-small cell lung cancer, several top-notch hospitals are leading the charge. In Boston, Massachusetts General Hospital stands out with an impressive 14 ongoing trials dedicated to this disease and a remarkable track record of 115 completed trials since their first recorded study in 2003. Meanwhile, at Dana-Farber Cancer Institute, also located in Boston, researchers are actively engaged in ten current non-small cell lung cancer trials and have contributed to 85 previous studies since their pioneering trial back in 1994.
Not far behind is Memorial Sloan Kettering Cancer Center based in New york City. With eight active non-small cell lung cancer trials and a solid history of conducting 102 prior investigations dating back to their first recorded trial in 2002, they demonstrate unwavering commitment to advancing knowledge and treatment options. Traveling further south brings us to Virginia Cancer Specialists situated in Fairfax. Although smaller-scale than some of its counterparts, this institution plays a significant role with eight ongoing clinical trials for non-small cell lung cancer and has conducted a commendable total of forty-six studies since recording its initial trial back in2010.
Additionally contributing towards these advancements is Princess Margaret Cancer Centre located within Toronto's medical landscape where six current clinical tests specifically focus on cases related to such carcinomas which adds up working hand-in-hand with thirty-two previously held experiments; theirs can be traced back merely eight years ago from2013.
These esteemed hospitals showcase not only dedication but also innovation as they strive tirelessly towards improving treatments for non-small cell lung cancer patients worldwide through groundbreaking research initiatives. Each new discovery or breakthrough brings hope that we are making progress toward more effective therapies for this challenging condition.
Which are the best cities for non-small cell lung cancer clinical trials?
When it comes to non-small cell lung cancer clinical trials, several cities have emerged as leaders in research and development. Boston, Massachusetts boasts the highest number of active trials with 61 ongoing studies focused on investigating treatments like encorafenib, PF-07284890, and Pembrolizumab. New york, New York follows closely behind with 50 active trials exploring various treatment options including PF-07284890, encorafenib, and LY3537982. Los Angeles, California is also a prominent city for clinical trials with 29 ongoing studies investigating treatments such as PF-07284890, Sasanlimab, and Amivantamab. These cities offer individuals battling non-small cell lung cancer access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment outcomes.
Which are the top treatments for non-small cell lung cancer being explored in clinical trials?
Non-small cell lung cancer (NSCLC) research offers a ray of hope through promising treatments currently under exploration in clinical trials. Amivantamab, a relatively new contender introduced in 2016, is making waves with four active trials and 13 all-time NSCLC studies. Osimertinib follows closely behind, having entered the scene in 2015 and now participating in two ongoing trials among its impressive portfolio of 83 all-time NSCLC trials. Additionally, Nivolumab and Pembrolizumab have both made significant strides since their introduction in 2011: each involved in two active NSCLC studies while boasting an incredible record of 122 and 210 all-time clinical trials respectively. With the tireless efforts of researchers, these treatments offer renewed optimism for patients battling non-small cell lung cancer around the world.
What are the most recent clinical trials for non-small cell lung cancer?
Exciting advancements in the field of non-small cell lung cancer (NSCLC) research offer hope for improved treatment options. Prominent among these recent clinical trials is a Phase 2 study focusing on dose expansion, which builds upon the promising results from Phase 1 and Phase 2 trials conducted earlier this year. Additionally, the combination therapy of Amivantamab Plus Lazertinib has shown potential as a background anti-cancer treatment for NSCLC patients. Another trial explores dose escalation strategies in Part 1, aiming to fine-tune treatment approaches through careful evaluation and monitoring. Moreover, an ongoing Phase 3 trial investigates the efficacy of Pembrolizumab combined with Sacituzumab Govitecan. Lastly, another intriguing study focuses on CISH CRISPR TIL in conjunction with PD-L1 inhibitors specifically for NSCLC patients who test positive for PD-L1 expression. These cutting-edge investigations provide encouraging prospects for advancing NSCLC management and improving patient outcomes.
What non-small cell lung cancer clinical trials were recently completed?
Several recently concluded clinical trials have made significant strides in the field of non-small cell lung cancer (NSCLC) research. Notably, Erasca, Inc.'s trial investigating ERAS-007 was completed in September 2021, while EMD Serono Research & Development Institute, Inc.'s M1231 trial concluded in January 2021. Additionally, Cantargia AB's CAN04 trial finished in September 2020 and Gan and Lee Pharmaceuticals' GLR2007 study wrapped up in July 2020. These advancements demonstrate ongoing efforts to advance treatment options for NSCLC patients and highlight the dedication of researchers working towards improved outcomes for this challenging disease.